Search Results

Royal Philips announced that it has completed the cancellation of 15,134,054 of its shares.

Cardiosense, Inc., a Chicago-based digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations.

Curis, Inc. today announced that it has entered into definitive agreements led by existing investors for the purchase of 18.4 million of its shares of common stock at a purchase price of $0.82 per share in a registered direct offering priced at-the-market under Nasdaq rules.

The Medical Device Contract Research Organization Market size is expected to surpass around US$ 15.1 billion by 2030 from valued at US$ 7.3 billion in 2020 with a CAGR of 9.6% from 2021 to 2030.

Pharmaron Beijing Co., Limited announced that their Liverpool, UK based Gene Therapy CDMO has received a prestigious grant from the UK Government’s Life Sciences Innovation Manufacturing Fund to expand their viral vector and DNA manufacturing facilities for more than 8,000 sqM.

Latest Study on “Epilepsy Therapeutics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

3Spine, Inc., a medical device company developing a transformational alternative to lumbar spinal fusion, today announced achievement of US clinical trial enrollment, with 151 completed MOTUS lumbar total joint replacement surgeries and 174 real-world posterior lumbar fusions as of December 2023.

Madrigal Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 1,248,098 shares of its common stock at a public offering price of $151.69 per share, and, to certain investors, pre-funded warrants to purchase 2,048,098 shares of common stock at a price of $151.6899 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant.

Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with Parkinson’s disease